Maggiori informazioni sul libro
In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the female Steve Jobs: a brilliant Stanford dropout whose startup "unicorn" promised to revolutionize the medical industry with a machine that would make blood tests significantly faster and easier. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in a fundraising round that valued the company at 9 billion dollars, putting Holmes's worth at an estimated 4.7 billion dollars. There was just one problem: The technology didn't work. For years, Holmes had been misleading investors, FDA officials, and her own employees. When John Carreyrou, working at The Wall Street Journal, got a tip from a former Theranos employee and started asking questions, both Carreyrou and the Journal were threatened with lawsuits. Undaunted, the newspaper ran the first of dozens of Theranos articles in late 2015. By early 2017, the company's value was zero and Holmes faced potential legal action from the government and her investors. The biggest corporate fraud since Enron is a cautionary tale set amid the bold promises and gold-rush frenzy of Silicon Valley
Acquisto del libro
Bad blood. Secrets and lies in a Silicon Valley startup, John Carreyrou
- Lingua
- Pubblicato
- 2018
- product-detail.submit-box.info.binding
- (In brossura)
Metodi di pagamento
Qui potrebbe esserci la tua recensione.
- Lingua
- Inglese
- Autori
- John Carreyrou
- Editore
- Picador
- Pubblicato
- 2018
- Formato
- In brossura
- Pagine
- 339
- ISBN10
- 1509868070
- ISBN13
- 9781509868070
- Serie
- Tag
- Saggistica, Commercio, Storie vere, Biografie, Auto-aiuto, Regali per le donne, Imprenditoria, Sangue, Inganno, illusione, Silicon Valley
- Prima pubblicazione
- 2018
- Titolo originale
- Bad Blood: Secrets and Lies in a Silicon Valley Startup
- Valutazione
- 4,45 su 5
- Descrizione
- In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the female Steve Jobs: a brilliant Stanford dropout whose startup "unicorn" promised to revolutionize the medical industry with a machine that would make blood tests significantly faster and easier. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in a fundraising round that valued the company at 9 billion dollars, putting Holmes's worth at an estimated 4.7 billion dollars. There was just one problem: The technology didn't work. For years, Holmes had been misleading investors, FDA officials, and her own employees. When John Carreyrou, working at The Wall Street Journal, got a tip from a former Theranos employee and started asking questions, both Carreyrou and the Journal were threatened with lawsuits. Undaunted, the newspaper ran the first of dozens of Theranos articles in late 2015. By early 2017, the company's value was zero and Holmes faced potential legal action from the government and her investors. The biggest corporate fraud since Enron is a cautionary tale set amid the bold promises and gold-rush frenzy of Silicon Valley